International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials

Cytotherapy

Volumn 18, Issue 2, 2015, Pages 151-159

  Galipeau, Jacques ^a   Krampera, Mauro ^b   Barrett, John ^c   Dazzi, Francesco ^d   Deans, Robert J ^e   DeBruijn, Joost ^f   Dominici, Massimo ^g   Fibbe, Willem E ^h   Gee, Adrian P ⁱ   Gimble, Jeffery M ^j   Hematti, Peiman ^k   Koh, Mickey B C ^l,y   LeBlanc, Katarina ^m   Martin, Ivan ⁿ   McNiece, Ian K ^o   Mendicino, Michael ^p   Oh, Steve ^q   Ortiz, Luis ^r   Phinney, Donald G ^s   Planat, Valerie ^t   Shi, Yufang ^u,z   Stroncek, David F ^v   Viswanathan, Sowmya ^w   Weiss, Daniel J ^x   Sensebe, Luc ^t   more..

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VERONA   (Italy)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e ATHERSYS INC   (United States)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ TEXAS CHILDREN S HOSPITAL   (United States)

^j TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF WISCONSIN   (United States)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

^m KAROLINSKA INSTITUTE   (Sweden)

ⁿ UNIVERSITY HOSPITAL BASEL   (Switzerland)

^o UNIVERSITY OF TEXAS   (United States)

^p Mesoblast Limited   (Australia)

^q AGENCY FOR SCIENCE   (Singapore)

^r UNIVERSITY OF PITTSBURGH   (United States)

^s SCRIPPS RESEARCH INSTITUTE   (United States)

^t CNRS   (France)

^u INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^v NATIONAL INSTITUTES OF HEALTH   (United States)

^w UNIVERSITY HEALTH NETWORK   (Canada)

^x UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^y HEALTH SCIENCES AUTHORITY   (Singapore)

^z MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

more..

Author keywords

clinical trials; immune functional testing; ISCT; matrix assays; Mesenchymal Stromal cells; potency assays; release assays

Indexed keywords

ANALYTIC METHOD; ARTICLE; ASSAY; AUTOIMMUNE DISEASE; BIOASSAY; CELL THERAPY; CLINICAL TRIAL (TOPIC); FLOW CYTOMETRY; HUMAN; IMMUNE FUNCTIONAL ASSAY; IMMUNOASSAY; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IN VITRO STUDY; MEASUREMENT; MESENCHYMAL STROMA CELL; NONHUMAN; PLASTICITY; PRIORITY JOURNAL; REGISTRATION; RELEASE ASSAY; RNA ANALYSIS; SOCIETY; TISSUE REPAIR; BIOLOGICAL THERAPY; CYTOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; PROCEDURES;

BIOLOGICAL MARKER;

BIOLOGICAL ASSAY; BIOMARKERS; CELL- AND TISSUE-BASED THERAPY; FLOW CYTOMETRY; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS;

EID: 84962117259     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2015.11.008     Document Type: Article

References (55)

1. [1] Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8 (2006), 315–317 150.
2. [2] Phinney, D.G., Galipeau, J., Krampera, M., Martin, I., Shi, Y., Sensebe, L., MSCs: science and trials. Nat Med, 19, 2013, 812 432.
3. [3] Wang, Y., Chen, X., Cao, W., Shi, Y., Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol 15 (2014), 1009–1016 446.
4. [4] Mendicino, M., Bailey, A.M., Wonnacott, K., Puri, R.K., Bauer, S.R., MSC-based product characterization for clinical trials: an FDA perspective. Cell Stem Cell 14 (2014), 141–145 439.
5. [5] Salmikangas, P., Menezes-Ferreira, M., Reischl, I., Tsiftsoglou, A., Kyselovic, J., Borg, J.J., et al. Manufacturing, characterization and control of cell-based medicinal products: challenging paradigms toward commercial use. Regen Med 10 (2015), 65–78 447.
6. [6] Lehman, N., Cutrone, R., Raber, A., Perry, R., Van't Hof, W., Deans, R., et al. Development of a surrogate angiogenic potency assay for clinical-grade stem cell production. Cytotherapy 14 (2012), 994–1004 440.
7. [7] Kebriaei, P., Isola, L., Bahceci, E., Holland, K., Rowley, S., McGuirk, J., et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 15 (2009), 804–811 149.
8. [8] Galipeau, J., Krampera, M., The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteria. Cytotherapy 17 (2015), 125–127 445.
9. [9] Krampera, M., Galipeau, J., Shi, Y., Tarte, K., Sensebe, L., Immunological characterization of multipotent mesenchymal stromal cells—the International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 15 (2013), 1054–1061 250.
10. [10] Deans, R., Towards the creation of a standard MSC line as a calibration tool. Cytotherapy 17 (2015), 1167–1168 443.
11. [11] Salem, B., Miner, S., Hensel, N.F., Battiwalla, M., Keyvanfar, K., Stroncek, D.F., et al. Quantitative activation suppression assay to evaluate human bone marrow-derived mesenchymal stromal cell potency. Cytotherapy, 17, 2015, 1675 448.
12. [12] Krampera, M., Mesenchymal stromal cell “licensing”: a multistep process. Leukemia 25 (2011), 1408–1414 138.
13. [13] Francois, M., Romieu-Mourez, R., Li, M., Galipeau, J., Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 20 (2012), 187–195 15.
14. [14] Menard, C., Pacelli, L., Bassi, G., Dulong, J., Bifari, F., Bezier, I., et al. Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells Dev 22 (2013), 1789–1801 4443668498.
15. [15] Chinnadurai, R., Copland, I.B., Ng, S., Garcia, M., Prasad, M., Arafat, D., et al. Mesenchymal stromal cells derived from Crohn's patients deploy indoleamine 2,3-dioxygenase mediated immune suppression, independent of autophagy. Mol Ther 23 (2015), 1248–1261 416.
16. [16] Viswanathan, S., Keating, A., Deans, R., Hematti, P., Prockop, D., Stroncek, D.F., et al. Soliciting strategies for developing cell-based reference materials to advance mesenchymal stromal cell research and clinical translation. Stem Cells Dev 23 (2014), 1157–1167 4414027980.
17. [17] Croitoru-Lamoury, J., Lamoury, F.M., Zaunders, J.J., Veas, L.A., Brew, B.J., Human mesenchymal stem cells constitutively express chemokines and chemokine receptors that can be upregulated by cytokines, IFN-beta, and Copaxone. J Interferon Cytokine Res 27 (2007), 53–64 344.
18. [18] Chamberlain, G., Smith, H., Rainger, G.E., Middleton, J., Mesenchymal stem cells exhibit firm adhesion, crawling, spreading and transmigration across aortic endothelial cells: effects of chemokines and shear. PLoS ONE, 6, 2011, e25663 3453182247.
19. [19] Feng, Y., Yu, H.M., Shang, D.S., Fang, W.G., He, Z.Y., Chen, Y.H., The involvement of CXCL11 in bone marrow-derived mesenchymal stem cell migration through human brain microvascular endothelial cells. Neurochem Res 39 (2014), 700–706 346.
20. [20] Tang, K.C., Trzaska, K.A., Smirnov, S.V., Kotenko, S.V., Schwander, S.K., Ellner, J.J., et al. Down-regulation of MHC II in mesenchymal stem cells at high IFN-gamma can be partly explained by cytoplasmic retention of CIITA. J Immunol 180 (2008), 1826–1833 347.
21. [21] Ren, G., Zhao, X., Zhang, L., Zhang, J., L'Huillier, A., Ling, W., et al. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol 184 (2010), 2321–2328 3532881946.
22. [22] Kimura, K., Nagano, M., Salazar, G., Yamashita, T., Tsuboi, I., Mishima, H., et al. The role of CCL5 in the ability of adipose tissue-derived mesenchymal stem cells to support repair of ischemic regions. Stem Cells Dev 23 (2014), 488–501 3493928761.
23. [23] Yang, X., Du, J., Xu, X., Xu, C., Song, W., IFN-gamma-secreting-mesenchymal stem cells exert an antitumor effect in vivo via the TRAIL pathway. J Immunol Res, 2014, 2014, 318098 3504058226.
24. [24] Romieu-Mourez, R., Francois, M., Boivin, M.N., Bouchentouf, M., Spaner, D.E., Galipeau, J., Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J Immunol 182 (2009), 7963–7973 351.
25. [25] Schenk, S., Mal, N., Finan, A., Zhang, M., Kiedrowski, M., Popovic, Z., et al. Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells 25 (2007), 245–251 352.
26. [26] Chinnadurai, R., Copland, I.B., Patel, S.R., Galipeau, J., IDO-independent suppression of T cell effector function by IFN-gamma-licensed human mesenchymal stromal cells. J Immunol 192 (2014), 1491–1501 217.
27. [27] Bai, L., Lennon, D.P., Caplan, A.I., DeChant, A., Hecker, J., Kranso, J., et al. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat Neurosci 15 (2012), 862–870 3563427471.
28. [28] Francois, M., Birman, E., Forner, K.A., Gaboury, L., Galipeau, J., Adoptive transfer of mesenchymal stromal cells accelerates intestinal epithelium recovery of irradiated mice in an interleukin-6-dependent manner. Cytotherapy 14 (2012), 1164–1170 4.
29. [29] Naji, A., Rouas-Freiss, N., Durrbach, A., Carosella, E.D., Sensebe, L., Deschaseaux, F., Concise review: combining human leukocyte antigen G and mesenchymal stem cells for immunosuppressant biotherapy. Stem Cells 31 (2013), 2296–2303 357.
30. [30] Rafei, M., Hsieh, J., Fortier, S., Li, M., Yuan, S., Birman, E., et al. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood 112 (2008), 4991–4998 57.
31. [31] Bladergroen, B.A., Meijer, C.J., ten Berge, R.L., Hack, C.E., Muris, J.J., Dukers, D.F., et al. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?. Blood 99 (2002), 232–237 386.
32. [32] Li, H., Jiang, Y., Jiang, X., Guo, X., Ning, H., Li, Y., et al. CCR7 guides migration of mesenchymal stem cell to secondary lymphoid organs: a novel approach to separate GvHD from GvL effect. Stem Cells 32 (2014), 1890–1903 364.
33. [33] Kagiwada, H., Yashiki, T., Ohshima, A., Tadokoro, M., Nagaya, N., Ohgushi, H., Human mesenchymal stem cells as a stable source of VEGF-producing cells. J Tissue Eng Regen Med 2 (2008), 184–189 365.
34. [34] Hung, S.C., Pochampally, R.R., Hsu, S.C., Sanchez, C., Chen, S.C., Spees, J., et al. Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. PLoS ONE, 2, 2007, e416 3661855077.
35. [35] Campeau, P.M., Rafei, M., Boivin, M.N., Sun, Y., Grabowski, G.A., Galipeau, J., Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood 114 (2009), 3181–3190 3682925728.
36. [36] Podechard, N., Fardel, O., Corolleur, M., Bernard, M., Lecureur, V., Inhibition of human mesenchymal stem cell-derived adipogenesis by the environmental contaminant benzo(a)pyrene. Toxicol in Vitro 23 (2009), 1139–1144 384.
37. [37] Qi, Y., Jiang, D., Sindrilaru, A., Stegemann, A., Schatz, S., Treiber, N., et al. TSG-6 released from intradermally injected mesenchymal stem cells accelerates wound healing and reduces tissue fibrosis in murine full-thickness skin wounds. J Invest Dermatol 134 (2014), 526–537 369.
38. [38] Casey, M.L., MacDonald, P.C., Keratinocyte growth factor expression in the mesenchymal cells of human amnion. J Clin Endocrinol Metab 82 (1997), 3319–3323 370.
39. [39] Greenbaum, A., Hsu, Y.M., Day, R.B., Schuettpelz, L.G., Christopher, M.J., Borgerding, J.N., et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature 495 (2013), 227–230 3823600148.
40. [40] Soland, M.A., Bego, M., Colletti, E., Zanjani, E.D., St Jeor, S., Porada, C.D., et al. Mesenchymal stem cells engineered to inhibit complement-mediated damage. PLoS ONE, 8, 2013, e60461 3813608620.
41. [41] Yoo, S.W., Chang, D.Y., Lee, H.S., Kim, G.H., Park, J.S., Ryu, B.Y., et al. Immune following suppression mesenchymal stem cell transplantation in the ischemic brain is mediated by TGF-beta. Neurobiol Dis 58 (2013), 249–257 385.
42. [42] Brooke, G., Tong, H., Levesque, J.P., Atkinson, K., Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta. Stem Cells Dev 17 (2008), 929–940 378.
43. [43] Ries, C., Egea, V., Karow, M., Kolb, H., Jochum, M., Neth, P., MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood 109 (2007), 4055–4063 377.
44. [44] Li, Y., Lin, F., Mesenchymal stem cells are injured by complement after their contact with serum. Blood 120 (2012), 3436–3443 3763482856.
45. [45] Yang, K., Wang, J., Xiang, A.P., Zhan, X., Wang, Y., Wu, M., et al. like receptors control the survival of mesenchymal stem cells. Cell Death Dis, 4, 2013, e967 3753877571.
46. [46] Schweizer, R., Kamat, P., Schweizer, D., Dennler, C., Zhang, S., Schnider, J.T., et al. Bone marrow-derived mesenchymal stromal cells improve vascular regeneration and reduce leukocyte-endothelium activation in critical ischemic murine skin in a dose-dependent manner. Cytotherapy 16 (2014), 1345–1360 374.
47. [47] Catrysse, L., Vereecke, L., Beyaert, R., van Loo, G., A20 in inflammation and autoimmunity. Trends Immunol 35 (2014), 22–31 373.
48. [48] Francois, M., Copland, I.B., Yuan, S., Romieu-Mourez, R., Waller, E.K., Galipeau, J., Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-gamma licensing. Cytotherapy 14 (2012), 147–152 113279133.
49. [49] Giuliani, M., Bennaceur-Griscelli, A., Nanbakhsh, A., Oudrhiri, N., Chouaib, S., Azzarone, B., et al. TLR ligands stimulation protects MSC from NK killing. Stem Cells 32 (2014), 290–300 372.
50. [50] Ringe, J., Strassburg, S., Neumann, K., Endres, M., Notter, M., Burmester, G.R., et al. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem 101 (2007), 135–146 362.
51. [51] Gieseke, F., Bohringer, J., Bussolari, R., Dominici, M., Handgretinger, R., Muller, I., Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 116 (2010), 3770–3779 361.
52. [52] Wei, F.Y., Leung, K.S., Li, G., Qin, J., Chow, S.K., Huang, S., et al. Low intensity pulsed ultrasound enhanced mesenchymal stem cell recruitment through stromal derived factor-1 signaling in fracture healing. PLoS ONE, 9, 2014, e106722 3604152330.
53. [53] Hall, S.R., Tsoyi, K., Ith, B., Padera, R.F. Jr, Lederer, J.A., Wang, Z., et al. Mesenchymal stromal cells improve survival during sepsis in the absence of heme oxygenase-1: the importance of neutrophils. Stem Cells 31 (2013), 397–407 3593572335.
54. [54] Egea, V., Zahler, S., Rieth, N., Neth, P., Popp, T., Kehe, K., et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) regulates mesenchymal stem cells through let-7f microRNA and Wnt/beta-catenin signaling. Proc Natl Acad Sci U S A 109 (2012), E309–16 3583277529.
55. [55] Ortiz, L.A., Dutreil, M., Fattman, C., Pandey, A.C., Torres, G., Go, K., et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A 104 (2007), 11002–11007 PMID 17569781; 4491891813.